Sema4 will use its next-generation sequencing testing services to identify patients with solid tumors harboring NRG1 fusions for Merus' Phase I/II drug trial.
The FDA has issued a clinical hold on the company's Phase I/II clinical trial of BPX-601 in patients with advanced pancreatic, gastric, and prostate cancer.
The study, slated to begin in the first half of 2021, follows recent discussion with the FDA and promising Phase II data presented at the ASH annual meeting.
Researchers presented data exploring CLL patients' outcomes on fixed-duration combination regimens and on using uMRD to decide which patients can stop treatment.
Kymriah and Yescarta were evaluated in indolent NHL subtypes, and Yescarta was evaluated in the front-line setting for high-risk large B-cell lymphoma.